Interações de Vitamina K

Patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von Willebrand's disease, the thrombocytopenias, thrombasthenia and other ill-defined hereditary platelet dysfunctions, severe vitamin K deficiency and severe liver damage). (bula de Butalbital + ácido acetilsalicílico + cafeína, Contraindicações)

WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY and INCREASED RISK OF BLEEDING WITH CONCOMITANT USE OF VITAMIN K ANTAGONISTS Increased risk of serious adverse reactions or death in patients with complete DPD deficiency • Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary. (bula de Capecitabina, Advertência em caixa preta)

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (bula de Fenitoína, Advertências e precauções)

Do not administer agents that enhance the risk of hemorrhage with fondaparinux sodium unless essential for the management of the underlying condition, such as vitamin K antagonists for the treatment of VTE. (bula de Fondaparinux, Advertências e precauções)

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (bula de Fosfenitoína, Advertências e precauções)

Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. (bula de Rifampicina, Advertências)

A vitamina K reduz o efeito anticoagulante da varfarina; mudanças repentinas no consumo, por suplementos ou pela dieta, podem desregular o INR. (NIH Office of Dietary Supplements, Vitamin K)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (bula de Apixabana, Advertências e precauções)

Some patients had serious bleeding including intracranial, retroperitoneal, and gastrointestinal requiring blood transfusion and/or administration of vitamin K. (bula de Bicalutamida, Advertências e precauções)

This can adversely affect patients with inherited (i.e. hemophilia) or acquired (i.e. liver disease or vitamin K deficiency) bleeding disorders. (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Advertências e precauções)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (bula de Cefazolina, Advertências e precauções)

Prothrombin time should be monitored in patients at risk, and exogenous vitamin K administered as indicated. (bula de Cefepima, Advertências e precauções)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. (bula de Cefixima, Advertências e precauções)

Prothrombin time should be monitored and exogenous vitamin K administered as indicated. (bula de Cefotetana, Advertências)

Patients with impaired vitamin K synthesis or low vitamin K stores (e.g., chronic hepatic disease and malnutrition) may require monitoring of prothrombin time during Ceftriaxone for Injection and Dextrose Injection treatment. (bula de Ceftriaxona, Advertências e precauções)

Vitamin K or Fat-Soluble Vitamin Deficiencies: Colesevelam hydrochloride may decrease absorption of fat-soluble vitamins. (bula de Colesevelam, Advertências e precauções)

For patients with APS (especially those who are triple-positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (bula de Dabigatrana, Advertências e precauções)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (bula de Edoxabana, Advertências e precauções)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (bula de Levotiroxina + liotironina, Interações medicamentosas)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (bula de Neomicina, Interações medicamentosas)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (bula de Orlistate, Interações medicamentosas)

Increased prothrombin time has been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. (bula de Pentoxifilina, Interações medicamentosas)

Drug Interactions Anticoagulants (oral) : Due to the potential inhibition of vitamin K activity by propylthiouracil, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. (bula de Propiltiouracila, Interações medicamentosas)

Warfarin and oral anticoagulants Cinchona alkaloids, including quinine, may have the potential to depress hepatic enzyme synthesis of vitamin K-dependent coagulation pathway proteins and may enhance the action of warfarin and other oral anticoagulants. (bula de Quinina, Interações medicamentosas)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (bula de Rivaroxabana, Advertências e precauções)

In vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively. (bula de Sugamadex, Advertências e precauções)

Drug Interactions Anticoagulants (oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers… (bula de Tiamazol (metimazol), Interações medicamentosas)

Cutaneous Reactions Parenteral administration of vitamin K replacements (including phytonadione injectable emulsion) may cause cutaneous reactions. (bula de Fitomenadiona (vitamina K1), Advertências e precauções)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (bula de Metilergometrina, Advertências)

Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. (bula de Primidona, Advertências)